SEARCH

SEARCH BY CITATION

References

  • 1
    Pouplard C, May MA, Regina S, Marchand M, Fusciardi J, Gruel Y. Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies. Br J Haematol 2005; 128: 83741.
  • 2
    Everett BM, Yeh R, Foo SY, Criss D, Van Cott EM, Laposata M, Avery EG, Hoffman WD, Walker J, Torchiana D, Jang IK. Prevalence of heparin/platelet factor 4 antibodies before and after cardiac surgery. Ann Thorac Surg 2007; 83: 5927.
  • 3
    Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006; 4: 75965.
  • 4
    Kuitunen A, Suojaranta-Ylinen R, Raivio P, Kukkonen S, Lassila R. Heparin-induced thrombocytopenia following cardiac surgery is associated with poor outcome. J Cardiothorac Vasc Anesth 2007; 21: 1822.
  • 5
    Liu JC, Lewis BE, Steen LH, Grassman ED, Bakhos M, Blakeman B, Wrona L, Leya F. Patency of coronary artery bypass grafts in patients with heparin-induced thrombocytopenia. Am J Cardiol 2002; 89: 97981.
  • 6
    Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med 1987; 316: 5819.
  • 7
    Pouplard C, Iochmann S, Renard B, Herault O, Colombat P, Amiral J, Gruel Y. Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood 2001; 97: 33002.
  • 8
    Arepally GM, Mayer IM. Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. Blood 2001; 98: 12524.
  • 9
    Mattioli AV, Bonetti L, Sternieri S, Mattioli G. Heparin-induced thrombocytopenia in patients treated with unfractionated hearin: prevalence of thrombosis in a 1 year follow-up. Ital Heart J 2000; 1: 3942.
  • 10
    Williams RT, Damaraju LV, Mascelli MA, Barnathan ES, Califf RM, Simoons ML, Deliargyris EN, Sane DC. Anti-platelet factor 4/heparin antibodies: an independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes. Circulation 2003; 107: 230712.
  • 11
    Matsuo T, Tomaru T, Kario K, Hirokawa T. Incidence of heparin-PF4 complex antibody formation and heparin-induced thrombocytopenia in acute coronary syndrome. Thromb Res 2005; 115: 47581.
  • 12
    Bennett-Guerrero E, Slaughter TF, White WD, Welsby IJ, Greenberg CS, El Moalem H, Ortel TL. Preoperative anti-PF4/heparin antibody level predicts adverse outcome after cardiac surgery. J Thorac Cardiovasc Surg 2005; 130: 156772.
  • 13
    Kress DC, Aronson S, McDonald ML, Malik MI, Divgi AB, Tector AJ, Downey FX III, Anderson AJ, Stone M, Clancy C. Positive heparin-platelet factor 4 antibody complex and cardiac surgical outcomes. Ann Thorac Surg 2007; 83: 173743.
  • 14
    Gluckman TJ, Segal JB, Fredde NL, Saland KE, Jani JT, Walenga JM, Prechel MM, Citro KM, Zidar DA, Fox E, Schulman SP, Kickler TS, Rade JJ. Incidence of antiplatelet factor 4/heparin antibody induction in patients undergoing percutaneous coronary revascularization. Am J Cardiol 2005; 95: 7447.
  • 15
    Desai MY, Lai S, Barmet C, Weiss RG, Stuber M. Reproducibility of 3D free-breathing magnetic resonance coronary vessel wall imaging. Eur Heart J 2005; 26: 23204.
  • 16
    Prechel MM, Woznica MA, McDonald MK, Jeske WP, Walenga JM. The impact of Non-H:PF4 antibodies on results of the serotonin release assay for heparin-induced thrombocytopenia. ASH Annu Meet Abstr 2005; 106: 3952.
  • 17
    Warkentin TE, Sheppard JI, Moore JC, Sigouin CS, Kelton JG. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost 2008; 6: 130412.
  • 18
    Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB Jr, Lorenz TJ, Goyal A, Gibson M, Mack MJ, Gennevois D, Califf RM, Kouchoukos NT. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA 2005; 294: 244654.
  • 19
    Widimsky P, Straka Z, Stros P, Jirasek K, Dvorak J, Votava J, Lisa L, Budesinsky T, Kolesar M, Vanek T, Brucek P. One-year coronary bypass graft patency: a randomized comparison between off-pump and on-pump surgery angiographic results of the PRAGUE-4 trial. Circulation 2004; 110: 341823.
  • 20
    Jones CM, Athanasiou T, Dunne N, Kirby J, Aziz O, Haq A, Rao C, Constantinides V, Purkayastha S, Darzi A. Multi-detector computed tomography in coronary artery bypass graft assessment: a meta-analysis. Ann Thorac Surg 2007; 83: 3418.
  • 21
    Calaitges JG, Liem TK, Spadone D, Nichols WK, Silver D. The role of heparin-associated antiplatelet antibodies in the outcome of arterial reconstruction. J Vasc Surg 1999; 29: 77985.
  • 22
    Lindhoff-Last E, Eichler P, Stein M, Plagemann J, Gerdsen F, Wagner R, Ehrly AM, Bauersachs R. A prospective study on the incidence and clinical relevance of heparin-induced antibodies in patients after vascular surgery. Thromb Res 2000; 97: 38793.
  • 23
    Alexy T, Tucker S, Boyle S, Rowe VL, Weaver FA, Liebman HA. Heparin-platelet factor 4 antibodies are frequent after vascular surgery but are not a frequent cause of graft thrombosis or thrombocytopenia. J Vasc Surg 2008; 48: 37781.
  • 24
    Warkentin TE, Hayward CP, Smith CA, Kelly PM, Kelton JG. Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. J Lab Clin Med 1992; 120: 3719.
  • 25
    Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001; 344: 128692.
  • 26
    Greinacher A, Kohlmann T, Strobel U, Sheppard JA, Warkentin TE. The temporal profile of the anti-PF4/heparin immune response. Blood 2008; 113: 49706.